# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 674 results.
NeoVax With Nivolumab in Patients With Ovarian Cancer
Status: Recruiting
Last Changed: Oct 28, 2020
First Received: Jul 18, 2019
Disease(s): Ovarian Cancer
Intervention(s): Nivolumab, NeoVax, Core Needle Biopsy
Locations: Dana Farber Cancer Institute, Boston, Massachusetts, United States
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
Status: Recruiting
Last Changed: Jul 08, 2020
First Received: Apr 09, 2020
Disease(s): Ovarian Cancer
Intervention(s): Zafirlukast
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Status: Recruiting
Last Changed: Apr 23, 2019
First Received: Apr 23, 2019
Disease(s): Ovarian Cancer
Intervention(s): Anlotinib
Locations: The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
Status: Recruiting
Last Changed: Jan 27, 2020
First Received: May 22, 2018
Disease(s): Ovarian Cancer
Intervention(s): Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Platino-resistance in Ovarian Cancer
Status: Recruiting
Last Changed: May 08, 2020
First Received: May 17, 2019
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Patients treated with platinum based-chemotherapy
Locations: Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jan 03, 2020
First Received: Jan 03, 2020
Disease(s): Ovarian Cancer
Intervention(s): Niraparib
A Single-Center, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer
Status: Not yet recruiting
Last Changed: Sep 24, 2020
First Received: Sep 24, 2020
Disease(s): Epithelial Ovarian Cancer
Intervention(s): LCAR-M23 cells
Locations: Shanghai East Hospital, Shanghai, Shanghai, China
Efficacy of Letrozole in Recurrent Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jun 09, 2020
First Received: Jun 09, 2020
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Letrozole 2.5mg, Standard single agent chemotherapy
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Status: Recruiting
Last Changed: Oct 05, 2020
First Received: Jan 23, 2020
Disease(s): Ovarian Cancer
Intervention(s): Olaparib, Ceralasertib, Placebo to match olaparib
Locations: Research Site, Anchorage, Alaska, United States
Research Site, La Jolla, California, United States
Research Site, Long Beach, California, United States
Research Site, Los Angeles, California, United States
Research Site, West Hollywood, California, United States
... and 37 other locations.
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Status: Recruiting
Last Changed: Oct 26, 2020
First Received: Aug 11, 2017
Disease(s): Ovarian Cancer
Intervention(s): Fostamatinib and Paclitaxel
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States